Terpenoid Therapeutics, Inc.

Coralville, IA 52241

SBIR Award Summary

Total Number of Awards 9
Total Value of Awards $1.72MM
First Award Date 09/15/07
Most Recent Award Date 05/01/14

Key Personnel

Last Name Name Awards Contact
Neighbors Jeffrey D Neighbors 9

9 Awards Won

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-13-089
Budget: 05/01/14 - 04/30/15

DESCRIPTION (provided by applicant): Chondrosarcoma is the second most common primary tumor of the bone having an incidence of 8 per million people in the US population over age 80. Research, particularly on cancer of the breast, has made great strides in curtailment of disease with chemo and radiation therapy. However, surgical removal remains...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-12-088
Budget: 09/01/13 - 08/31/14

DESCRIPTION (provided by applicant): The goal of these studies is to determine the efficacy of proprietary geranylgeranyl diphosphate synthase inhibitors (GGSIs), for inhibition of osteoclast mediated bone resorption in comparison to current standard-of-care agents. We have developed a group of proprietary bisphosphonates containing isoprene sub...

Phase 2 STTR

Agency: Department of Health & Human Services
Topic: PA-08-051
Budget: 09/15/10 - 09/14/12

DESCRIPTION (provided by applicant): According to the American Cancer Society an estimated 21,810 cases of primary malignant brain tumor will be reported in the US in 2008. The ACS also estimates that 13,070 deaths will occur due to these diseases in this year. This Phase II STTR program advocates the development of drugs for primary CNS cancers...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-09-080
Budget: 08/11/10 - 07/31/12

DESCRIPTION (provided by applicant): According to the American Cancer Society an estimated 182,000 cases of invasive breast cancer occurred in the US in 2008, with 40,000 deaths due to breast cancer. Among women with metastatic breast cancer, the 5-year survival rate is 27%. The studies proposed in this SBIR phase I application are designed to a...

Phase 2 STTR

Agency: Department of Health & Human Services
Topic: PA-08-051
Budget: 09/22/09 - 09/14/10

DESCRIPTION (provided by applicant): According to the American Cancer Society an estimated 21,810 cases of primary malignant brain tumor will be reported in the US in 2008. The ACS also estimates that 13,070 deaths will occur due to these diseases in this year. This Phase II STTR program advocates the development of drugs for primary CNS cancers...

Phase 2 STTR

Agency: Department of Health & Human Services
Topic: PA-08-051
Budget: 09/22/09 - 09/14/10

DESCRIPTION (provided by applicant): According to the American Cancer Society an estimated 21,810 cases of primary malignant brain tumor will be reported in the US in 2008. The ACS also estimates that 13,070 deaths will occur due to these diseases in this year. This Phase II STTR program advocates the development of drugs for primary CNS cancers...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-08-050
Budget: 04/06/09 - 03/31/11

DESCRIPTION (provided by applicant): The goal of these studies is the development of a treatment for hormone refractory prostate cancer based on the inhibition of an enzyme geranygeranyl disphosphate synthase (GGDPS). We have developed a group of proprietary bisphosphonates containing isoprene substructures that demonstrate highly potent and spe...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-06-21
Budget: 09/24/07 - 08/31/09

DESCRIPTION (provided by applicant): The overall goal of the proposed studies is to establish the feasibility of moving our novel class of GGDPS specific inhibitors into clinical development for treatment of myeloma and metastatic disease of the bone. The specificity that a number of these novel non-nitrogen- containing bisphosphonates, most not...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-06-21
Budget: 09/15/07 - 09/14/09

DESCRIPTION (provided by applicant): The overall goal of the proposed studies is to establish the feasibility of developing therapies for brain cancers such as glioblastoma multiforme from the schweinfurthin family of antiproliferative agents. These agents are highly toxic to CNS derived tumor cell lines in vitro and more importantly appear to e...